Trial: 202111115

A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART -007) in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/ Lymphoblastic Lymphoma (LBL)

Phase

I/II

Principal Investigator

Ghobadi, Armin

Disease Site

Lymphoid Leukemia; Non-Hodgkin Lymphoma

Learn more about this study at: clinicaltrials.gov